Top Medical News
Stephen Padilla, 16 hours ago
Adding fenofibrate to allopurinol or febuxostat reduces uric acid levels in patients with gout without showing any significant change in renal or hepatic functions, a recent study has shown. This suggests that cotreatment of fenofibrate with xanthine oxidase inhibitors is a reasonable option for treating gout in patients who have high triglyceride levels.
Pearl Toh, Yesterday
The anti-PD-1 immunotherapy pembrolizumab confers survival benefit over standard chemotherapy in patients with recurrent or metastatic head and neck cancer in the first-line setting, reveals the topline results of the KEYNOTE-048* study presented at ESMO 2018.
Roshini Claire Anthony, Yesterday

Dapagliflozin reduced the risk of hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) who had established or multiple risk factors for atherosclerotic cardiovascular disease (CVD), according to results of the DECLARE-TIMI 58* trial presented at AHA 2018. However, it did not reduce the incidence of major adverse cardiovascular events (MACE)**.

Yesterday

Cancer of the corpus uteri (uterine cancer) accounted for nearly 7 percent of all female cancers in Singapore between 2011 and 2015 and was the fourth most frequent female cancer among all Singaporeans. The majority of patients are diagnosed with cancer confined to the uterus and have a 5-year survival rate exceeding 90 percent, while the survival rate of stage IV endometrial cancer is approximately 20 percent. This highlights the importance of recognizing and detecting endometrial cancers early in the natural history.

2 days ago
Higher exposure to ticagrelor following myocardial infarction does not appear to contribute to an increased risk of intracranial haemorrhage, which is associated with age and prior cardiovascular morbidities, according to a study.
2 days ago
Prescription of antibiotic prophylaxis (AP) has decreased among all infective endocarditis (IE) risk groups, especially those at moderate risk, a recent study has shown. At the same time, there has been a significant increase in IE incidence among high-risk individuals, a borderline significant risk in moderate-risk individuals, and no change among those at low or unknown risk.
Pearl Toh, 3 days ago
Intraoperative remifentanil infusion was associated with increased requirement for opioids in post-anaesthesia care unit (PACU) and delayed discharge from PACU compared with intraoperative morphine or fentanyl in patients undergoing head and neck surgery lasting ≥2 hours, according to a local observational study.
Special Reports
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Dr. Robert Giugliano, Prof. Ulrich Laufs, Prof. Gaetano De Ferrari, Prof. Naveed Sattar, 11 Oct 2018

The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.

27 Sep 2018
PRALUENT – alirocumab 75 mg/mL and 150 mg/mL soln for inj - sanofi-aventis
27 Sep 2018
VICTOZA – Liraglutide 6 mg/mL soln for inj - Novo Nordisk
27 Sep 2018
SKYCELLFLU – Inactivated quadrivalent influenza vaccine (inj) 0.5 mL - AJ Biologics
Rachel Soon, 01 Sep 2018

MIMS Pharmacist presents an overview of a standardized extract of Pinus pinaster bark, and its potential role in slowing down the progression of diabetic retinopathy.

Rachel Soon, 25 Jul 2018

MIMS Pharmacist presents an overview of Lactobacillus plantarum 299v's physiological role, as well as contemporary research on its pharmacology and effects.

Conference Reports
Pearl Toh, 19 Nov 2018
The anti-PD-1 immunotherapy pembrolizumab confers survival benefit over standard chemotherapy in patients with recurrent or metastatic head and neck cancer in the first-line setting, reveals the topline results of the KEYNOTE-048* study presented at ESMO 2018.
Roshini Claire Anthony, 19 Nov 2018

Dapagliflozin reduced the risk of hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) who had established or multiple risk factors for atherosclerotic cardiovascular disease (CVD), according to results of the DECLARE-TIMI 58* trial presented at AHA 2018. However, it did not reduce the incidence of major adverse cardiovascular events (MACE)**.

Pearl Toh, 16 Nov 2018
Lipid-lowering with ezetimibe monotherapy was effective for the primary prevention of atherosclerotic cardiovascular (CV) events in middle- to high-risk elderly Japanese patients with hypercholesterolaemia, according to the EWTOPIA75* study presented at AHA 2018 Scientific Sessions.
Elaine Soliven, 15 Nov 2018
The administration of sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, during hospitalization significantly reduces the N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels among patients with acute decompensated heart failure (ADHF) and reduced ejection fraction compared with enalapril, according to the PIONEER-HF* trial presented at AHA 2018 Scientific Sessions.
Elvira Manzano, 11 Nov 2018
Low-dose methotrexate, which is approved for the treatment of rheumatoid arthritis (RA) and other autoimmune disorders, has shown unexpectedly disappointing results in preventing cardiovascular (CV) events among patients with a prior myocardial infarction (MI) or multivessel coronary disease, according to CIRT*, potentially ruling out what could be an affordable option for treating inflammation related to atherosclerosis.
Roshini Claire Anthony, 09 Nov 2018

Patients with advanced, unresectable melanoma may derive overall survival (OS) and progression-free survival (PFS) benefits when treated with a nivolumab plus ipilimumab combination or nivolumab alone, according to 4-year results of the phase III CheckMate 067* trial presented at ESMO 2018.

Audrey Abella, 09 Nov 2018
The drug combination comprising gemcitabine, cisplatin, and S-1 (GCS) led to significant survival benefits compared with the standard dual chemotherapy regimen of gemcitabine and cisplatin (GC) among patients with advanced biliary tract* cancer (BTC), according to results of the KHB01401–MITSUBA** trial presented at ESMO 2018.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download